Next Article in Journal
Pathology Re-Review as an Essential Component of Breast Cancer Management
Previous Article in Journal
In This Issue of Current Oncology
Current Oncology is published by MDPI from Volume 28 Issue 1 (2021). Previous articles were published by another publisher in Open Access under a CC-BY (or CC-BY-NC-ND) licence, and they are hosted by MDPI on mdpi.com as a courtesy and upon agreement with Multimed Inc..
Article

Cost-Effectiveness of Oxaliplatin in the Adjuvant Treatment of Colon Cancer in Canada

1
Cornerstone Research Group Inc., Burlington, ON, Canada
2
Ottawa Hospital Regional Cancer Centre, Ottawa, ON, Canada
3
Sanofi–Aventis Canada Inc., Laval, QC H7L 4A8, Canada
*
Author to whom correspondence should be addressed.
Received: 6 November 2009 / Revised: 3 December 2009 / Accepted: 8 January 2010 / Published: 1 February 2010
Objective: The cost-effectiveness of oxaliplatin in combination with 5-fluorouracil/leucovorin (5FU/LV)—the FOLFOX regimen—was compared with that of 5FU/LV alone as adjuvant therapy for patients with stage III colon cancer, from the perspective of the Cancer Care Ontario New Drug Funding Program. In the MOSAIC (Multicenter International Study of Oxaliplatin/5-Fluorouracil/Leucovorin in the Adjuvant Treatment of Colon Cancer) trial, the FOLFOX regimen significantly improved disease-free survival. The MOSAIC trial formed the basis of the present analysis. Methodology: Extrapolated patient-level data from the MOSAIC trial were used to model patient outcomes from treatment until death. Utilities were obtained from the literature. Resource utilization data were derived from the MOSAIC trial and supplemented with data from the literature. Unit costs were obtained from the Ontario Ministry of Health and Long-Term Care, the London Health Sciences Centre, and the literature. Results: Lifetime incremental cost-effectiveness ratios for FOLFOX compared with 5FU/LV were CA$14,266 per disease-free year, CA$23,598 per life-year saved, and CA$24,104 per quality adjusted life-year (QALY) gained, discounting costs and outcomes at 5% per annum. These results were stable for a wide range of inputs; only utility values associated with relapse seemed to influence the cost-effectiveness ratios observed. Conclusions: With an incremental cost of CA$24,104 per QALY gained, FOLFOX is a cost-effective adjuvant treatment for stage III colon cancer. Compared with 5FU/LV alone, this regimen offers better clinical outcomes and provides good value for money.
Keywords: oxaliplatin; cost-effectiveness; adjuvant; chemotherapy; colon cancer; 5fu/lv oxaliplatin; cost-effectiveness; adjuvant; chemotherapy; colon cancer; 5fu/lv
MDPI and ACS Style

Attard, C.L.; Maroun, J.A.; Alloul, K.; Grima, D.T.; Bernard, L.M. Cost-Effectiveness of Oxaliplatin in the Adjuvant Treatment of Colon Cancer in Canada. Curr. Oncol. 2010, 17, 17-24. https://0-doi-org.brum.beds.ac.uk/10.3747/co.v17i1.436

AMA Style

Attard CL, Maroun JA, Alloul K, Grima DT, Bernard LM. Cost-Effectiveness of Oxaliplatin in the Adjuvant Treatment of Colon Cancer in Canada. Current Oncology. 2010; 17(1):17-24. https://0-doi-org.brum.beds.ac.uk/10.3747/co.v17i1.436

Chicago/Turabian Style

Attard, C. L., J. A. Maroun, K. Alloul, D. T. Grima, and L. M. Bernard 2010. "Cost-Effectiveness of Oxaliplatin in the Adjuvant Treatment of Colon Cancer in Canada" Current Oncology 17, no. 1: 17-24. https://0-doi-org.brum.beds.ac.uk/10.3747/co.v17i1.436

Find Other Styles

Article Access Map by Country/Region

1
Only visits after 24 November 2015 are recorded.
Back to TopTop